
Can Mounjaro Help Teenagers Lose Weight? Major Study Finds 18.5% Drop In BMI
What Happened?
A new study published in JAMA shows that tirzepatide, marketed as Mounjaro, led to an 18.5% reduction in BMI among adolescents with obesity over 72 weeks. The trial involved 160 participants aged 12 to 18.
Key points
- The Phase 3 SURMOUNT-ADOLESCENTS trial involved 160 adolescents aged 12 to under 18.
- Participants receiving tirzepatide saw an average 18.5% reduction in BMI over 72 weeks.
- 79.6% of those on tirzepatide achieved at least a 5% reduction in BMI.
- 54% of participants no longer met the clinical BMI threshold for obesity by the end of the trial.
- Common side effects included gastrointestinal issues such as nausea and diarrhea.
Key insights
- The study suggests that tirzepatide may offer a new avenue for treating adolescent obesity.
- Long-term effects of tirzepatide on growth and development in teenagers remain uncertain.
- Medical supervision and lifestyle changes are essential for sustainable weight management.
Why it matters
The findings could influence treatment options for adolescents struggling with obesity.
Entities
Source
Times Now

